Pieris, Daiichi Sankyo Ink Anticalins Deal for up to $296M
By Cormac Sheridan
Wednesday, April 13, 2011
Pieris AG is banking 7 million (US$10.1 million) up front and could earn up to 200 million more in milestone payments and research funding from a discovery deal with Daiichi Sankyo, based around its anticalin protein scaffold technology.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.